Sarda Proteins Falls to 52-Week Low of Rs.66 Amidst Weak Financial Metrics

The stock opened with a gap down of 4.57% and despite touching an intraday high of Rs.72.61, it closed near its low point. The day’s trading saw a decline of 1.68%, yet the stock outperformed its sector by 5.19% on the same day. Notably, after 20 consecutive days of decline, Sarda Proteins recorded a gain today, signalling a potential short-term trend reversal. However, the stock’s trading pattern has been erratic, with one day of no trading activity in the last 20 days.

From a technical perspective, the stock price currently sits above its 100-day and 200-day moving averages but remains below its 5-day, 20-day, and 50-day moving averages. This mixed technical picture indicates some underlying support at longer-term levels, while shorter-term momentum remains subdued.

Over the past year, Sarda Proteins has recorded a return of -36.95%, significantly underperforming the Sensex, which has shown a positive return of 9.73% over the same period. The stock’s 52-week high was Rs.137.45, highlighting the extent of the decline to the current low. The broader market context shows the Sensex trading near its 52-week high, with a minor dip of 0.09% today, and maintaining a bullish stance above its 50-day and 200-day moving averages.

Financially, the company’s long-term fundamentals appear weak. Sarda Proteins has not declared results in the last six months, which adds to the uncertainty surrounding its financial health. The company’s ability to service its debt is notably constrained, with an average EBIT to interest ratio of 0.01, indicating minimal earnings before interest and taxes relative to interest obligations. This is a critical metric for assessing financial stability and debt servicing capacity.

Additionally, the company has reported losses, which is reflected in a negative return on equity (ROE). The stock is considered risky when compared to its average historical valuations, and its earnings before interest, taxes, depreciation, and amortisation (EBITDA) are negative. Profitability has also declined by 5% over the past year, further underscoring the financial pressures faced by the company.

In terms of market performance, Sarda Proteins has underperformed not only in the last year but also over longer periods such as three years and three months, when compared to the BSE500 index. This sustained underperformance highlights challenges in both near-term and long-term growth prospects as reflected in the stock price.

Despite the overall subdued performance, the company reported positive results in June 2025, with net sales for the half-year period reaching ₹109.55 million. This figure represents a substantial growth rate of 18,127.29%, indicating some areas of operational improvement or expansion. However, this growth in sales has not yet translated into profitability or improved financial ratios.

On the trading front, the stock’s erratic behaviour over the past month, including a day without trading and a recent gain after a prolonged decline, suggests volatility and uncertainty among market participants. The opening gap down today and the intraday price range between Rs.66 and Rs.72.61 reflect this unsettled trading environment.

In summary, Sarda Proteins’ fall to a 52-week low of Rs.66 is underpinned by a combination of weak financial metrics, negative profitability, and sustained underperformance relative to market benchmarks. While the stock shows some technical support at longer moving averages and recorded a brief gain after a series of declines, the overall financial data points to ongoing challenges in the company’s earnings and debt servicing capabilities.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →